Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (860)	1/18/1998 8:07:00 AM
From: Henry Volquardsen	Respond to of 1115

John, The initial press release had the phone number for HealthMed. I don't have it at the moment but will be able to get it tuesday. I will call next week and ask some questions about who they are, ownership and previous business dealings. Maybe you and some of the others can call as well. Technically Katz is not getting out. He still retains approximately two thirds of his equity, just not the voting rights. A question is if in the new set up he will have an equity satake in HealthMed? Henry

To: John Zwiener who wrote (860)	1/18/1998 8:51:00 AM
From: donald barton	Read Replies (1) \| Respond to of 1115

John, After some reflection, this is my take- purely conjectiure. Dr. Katz's decision to surrender the management of Lidak to Healthmed did not come as a reaction to the breakup of the BMS deal. Dr. Katz appears to be a measured individual and must have known the principals in Healthmed for some time to attempt to transfer management control. Trust lawyers don't turn these complicated documents around and file in 7 days. This deal was coming down the pike, and may not be a reaction to BMS's decision, as it might appear. Rather,there is a possibility that Squib became aware of this new affiliation and, if this is the same organization as reported in the Time magazine article, may have become uncomfortable with their background, methods,and practices. Squib may not have wanted the complications and bowed out. Bottom line- The drug works, Healthmed wants all the action for a small entry fee. No one has explained what Healthmed wants, besides control, for lending Lidak some money. Dr. Katz has annointed Healthmed. WHY? We need to know what the terms are?. I fear the toll that Healthmed would exact in management fees would be fiercesome! The Board and shareholders need more answers. There are too many unanswered questions.